Caris Life Sciences, Inc. (CAI) stock
CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.50−0.44 (-2.21%)
Close on Nov 18, 2026Market cap $5.51BP/E –Yield –
Caris Life Sciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Caris Life Sciences's operating income for the twelve months ending Sep 30, 2026 was $139.94M. For fiscal 2025 it was $45.11M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.11M | – |
| FY2024 | Dec 31, 2024 | -$257.12M | – |
| FY2023 | Dec 31, 2023 | -$319.55M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $19.32M | -40.8% |
| Q2 FY2026 | Jun 30, 2026 | $26.93M | – |
| Q1 FY2026 | Mar 31, 2026 | $5.28M | – |
| Q4 FY2025 | Dec 31, 2025 | $88.41M | – |
| Q3 FY2025 | Sep 30, 2025 | $32.64M | – |
| Q2 FY2025 | Jun 30, 2025 | -$17.99M | – |
| Q1 FY2025 | Mar 31, 2025 | -$57.95M | – |
| Q4 FY2024 | Dec 31, 2024 | -$37.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$60.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$67.01M | – |
See a number that looks wrong?